{"id":"NCT01206387","sponsor":"Sun Pharmaceutical Industries, Inc.","briefTitle":"Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis","officialTitle":"A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2010-12","completion":"2011-01","firstPosted":"2010-09-21","resultsPosted":"2014-08-07","lastUpdate":"2017-06-05"},"enrollment":120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Desoximetasone Spray 0.25%","otherNames":["Desoximetasone"]},{"type":"DRUG","name":"placebo comparator","otherNames":["vehicle"]}],"arms":[{"label":"active product","type":"EXPERIMENTAL"},{"label":"placebo comparator","type":"PLACEBO_COMPARATOR"}],"summary":"efficacy study in patients with moderate to severe plaque psoriasis.","primaryOutcome":{"measure":"Clinical Success","timeFrame":"28 days","effectByArm":[{"arm":"Desoximetasone Spray 0.25%","deltaMin":18,"sd":null},{"arm":"Placebo","deltaMin":3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28504031"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":60},"commonTop":["Application Site Dryness","Application Site Pruritus","Headache","Arthralgia","Diarrhoea"]}}